Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.

Pharmacogenomics - 1 Aug 2018

Klein Melissa D, Lee Craig R, Stouffer George A

Abstract excerpt

It is well established that the CYP2C19 nonfunctional *2 and *3 polymorphisms impair the bioactivation and antiplatelet effects of clopidogrel, and increase the risk of adverse cardiovascular events following percutaneous coronary intervention. In contrast, CYP2C19 genotype does not impact clinical response to prasugrel or ticagrelor. Recent studies have evaluated the impact of CYP2C19 genotype-guided selection...

Topics

Join the communities discussing this publication.

Acute Coronary Syndrome
Clopidogrel
Cytochrome P-450 CYP2C19
Genotype
Percutaneous Coronary Intervention

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Platelet Aggregation Inhibitors

Precision Medicine

Source

Identifiers

PMID: 30028231
DOI: 10.2217/pgs-2018-0072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.PMID 30028231Read ↗

Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.Semantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.Semantic proximity Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

Pharmacogenetics of Antiplatelet Therapy.Semantic proximity Read ↗

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure.Semantic proximity Read ↗

The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.Semantic proximity Read ↗

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.Semantic proximity Read ↗

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.